StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Dexmethylphenidate

HCID 154101
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
40431-64-9
Standard-SMILES
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
InChIKey
DUGOZIWVEXMGBE-CHWSQXEVSA-N
Summenformel
C14H19NO2
Durchschnittliche Molmasse
233,31 g/mol
Monoisotopische Masse
233,14157885

Überblick

Dexmethylphenidate is a methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate. It has a role as an adrenergic agent. It is an enantiomer of a methyl (S)-phenyl[(S)-piperidin-2-yl]acetate.

Namen und Bezeichner

Bevorzugter Name
Dexmethylphenidate
IUPAC
methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
Englischer Name
dexmethylphenidate
Summenformel
C14H19NO2
Molmasse
233.31

Namen und Synonyme

Dexmethylphenidated-threo-Methylphenidate(+)-threo-Methylphenidate40431-64-9dexmetilfenidatoAttenadeD-TMPM32RH9MFGPdexmethylphenidatummethyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetateCHEBI:51860methyl (R)-phenyl[(R)-piperidin-2-yl]acetate
Weitere Namen anzeigen
d-threo-FormDexaMethylphenedateDexmethylphenidate D9D-threo-Methylphenidate DISCONTINUED, offer M3256752-Piperidineacetic acid, α-phenyl-, methyl ester, (αR,2R)-
DTXSID70893769methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate2-Piperidineacetic acid, alpha-phenyl-, methyl ester, (alphaR,2R)-METHYL (2R)-PHENYL((2R)-PIPERIDIN-2-YL)ACETATEmethyl (R)-phenyl((R)-piperidin-2-yl)acetatemethyl (2R)-2-phenyl-2-((2R)-piperidin-2-yl)acetateRefChem:56469Methylphenidate d-threo-

Datenbank-Bezeichner

CAS
40431-64-9
PubChem CID
154101

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
0,2
Polarare Oberfläche (TPSA)
38,3 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
4
Schwere Atome
17
Formalladung
0
Komplexität
249

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

DEA NFLIS-Drug Category -> Piperidines/PEA

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

Human DrugsBreast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents
Melting Point>203
Physical DescriptionSolid

Physikochemische Eigenschaften

Siedepunkt
327.6 · 327.6±17.0 °C(Predicted)
Dichte
1.07 · 1.070±0.06 g/cm3(Predicted)
pka
9.51 · 9.51±0.10(Predicted)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Exposure Routes11-52%
Toxicity Summary · 1 Eintrag

Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.

Signs and Symptoms · 1 Eintrag

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

dexmethylphenidate

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataOral, Mouse: LD<sub>50</sub>=190mg/kg

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Protein Binding12-15% of dexmethylphenidate is protein bound. However, other studies have observed 15.2±5.2% protein binding in children and 16.2±1.1% in adults.
PharmacodynamicsDexmethylphenidate is the d-enantiomer of methylphenidate. This enantiomer is more pharmacologically active than the racemic mixture and may block norepinephrine and dopamine reuptake in synapses.
Mechanism of Action · 1 Eintrag

Methylphenidate inhibits dopamine and norepinephrine reuptake transporters in synapses, especially in the thalamus and striatum. One study shows no detectable difference in the caudal prefrontal cortex of treated or untreated monkeys, though multiple rat studies show activity on the prefrontal cortex. Imaging of human brains after administration of methylphenidate shows changes to blood flow of various regions of the brain including the striatum, supplementary motor area, and posterior parietal cortex.

Biological Half-LifeThe mean terminal half life is approximately 2.2 hours. However other studies have shown 3.8-3.9 hours, or 5.96 hours after intravenous administration and 5.69 hours following an oral dose.
Metabolism/Metabolites · 2 Einträge

Dexmethylphenidate is metabolised to the inactive metabolite ritalinic acid by carboxylesterase 1A1 in the liver. Other minor pathways metabolise dexmethylphenidate to the inactive metabolites 6-oxo-methylphenidate and p-hydroxy-methylphenidate which are de-esterified and conjugated into other unknown metabolites.

epatic, methylphenidate is metabolized primarily by de-esterification to ritalinic acid (&alpha;-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity. Route of Elimination: Renal Half Life: 2-4 hours

FDA Pharmacological Classification · 5 Einträge

Zugehörige Reaktionen

16
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 241544
HRID 241544als Produkt
Reaktionsgleichung von HRID 242139
HRID 242139als Produkt
Reaktionsgleichung von HRID 587133
HRID 587133als Produkt
Reaktionsgleichung von HRID 599388
HRID 599388als Produkt
Reaktionsgleichung von HRID 599389
HRID 599389als Edukt
Reaktionsgleichung von HRID 874176
HRID 874176als Produkt
Reaktionsgleichung von HRID 1019622
HRID 1019622als Produkt
Reaktionsgleichung von HRID 1020445
HRID 1020445als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
DTXSID
DTXSID70893769
ChEMBL
CHEMBL827
ChEBI
CHEBI:51860
UNII
M32RH9MFGP
Nikkaji
J343.157F

M32RH9MFGP

DEXMETHYLPHENIDATE

Established Pharmacologic Class [EPC] - Central Nervous System Stimulant

Physiologic Effects [PE] - Central Nervous System Stimulation

Dexmethylphenidate is a Central Nervous System Stimulant. The physiologic effect of dexmethylphenidate is by means of Central Nervous System Stimulation.

MeSH Pharmacological Classification · 2 Einträge

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Absorption, Distribution and Excretion · 4 Einträge

Taking dexmethylphenidate with or without food does not affect patients in a clinically relevant way. 90% of an oral dose is absorbed but as a result of hepatic first pass metabolism, oral bioavailability of dexmethylphenidate is 23% compared to l-methylphenidate with an oral bioavailability of 5%. Maximum concentration is generally reached in 1-1.5 hours.

Dexmethylphenidate is mainly eliminated renally. After 48 hours, 90% of the dose is collected in the urine and 3.3% is collected from feces.

2.65L/kg when administered intravenously.

0.40L/hr/kg following an intravenous dose and a renal clearance of 0.005L/hr/kg.

Cellular LocationsMembrane

Verwendung und Herstellung

UsesDexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment.

Anwendungen

VerwendenTreatment of attention deficit/hyperactivity disorder.

Ergänzende Hinweise

DefinitionChEBI: A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.